Focused On-demand Library for Glucosamine-6-phosphate isomerase 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q8TDQ7

UPID:

GNPI2_HUMAN

Alternative names:

Glucosamine-6-phosphate deaminase 2; Glucosamine-6-phosphate isomerase SB52

Alternative UPACC:

Q8TDQ7; B4DJF3; Q2VYF1; Q59EA7; Q8NCZ8; Q96BJ4; Q96NC6

Background:

Glucosamine-6-phosphate isomerase 2, also known as Glucosamine-6-phosphate deaminase 2, plays a pivotal role in the hexosamine pathway by catalyzing the conversion of alpha-D-glucosamine 6-phosphate into beta-D-fructose 6-phosphate. This enzyme is crucial for the biosynthesis of uridine diphosphate-N-acetyl-alpha-D-glucosamine, a key precursor in the production of hyaluronan, a component vital for tissue remodeling.

Therapeutic significance:

Understanding the role of Glucosamine-6-phosphate isomerase 2 could open doors to potential therapeutic strategies. Its involvement in the metabolic pathways that regulate tissue remodeling and hyaluronan synthesis highlights its potential as a target for therapeutic intervention in diseases characterized by abnormal tissue growth or repair.